| Efficacy and tolerability of botulinum toxin type a in patients with neurogenic detrusor overactivity and without concomitant anticholinergic therapy: comparison of two doses. | |
| | |
MedLine Citation:
|
PMID: 20674149 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
BACKGROUND: Botulinum toxin type A (BoNTA) has been reported to be effective for treatment of patients with neurogenic detrusor overactivity (NDO) refractory to anticholinergic agents. However, in most of the studies, the efficacy was associated with concomitant use of anticholinergics. OBJECTIVE: To evaluate the efficacy and tolerability of BoNTA and compare two different doses in patients with NDO without concomitant anticholinergics. DESIGN, SETTING, AND PARTICIPANTS: Between 2004 and 2006, adults with NDO refractory to anticholinergics or discontinued anticholinergics due to adverse events or contraindications from four different French clinical centres were included in a prospective, randomised, double-blind, comparative trial. Inclusion criteria were urinary incontinence (UI) resulting from NDO that could not be managed with anticholinergics. Patients with bladder cancer, lithiasis, or urinary infection were excluded. INTERVENTION: Patients were randomised to receive an intradetrusor injection of 500 U or 750 U of BoNTA. MEASUREMENTS: The initial evaluation (ie, clinical and urodynamic variables and quality of life [QoL]) was repeated at days 30, 90, 180, and 360. Primary outcome was complete continence rate at day 30. Secondary outcomes were cumulative incontinence rate, reappearance of leakages, pad usage, urodynamics, and QoL. RESULTS AND LIMITATIONS: Seventy-seven patients received 500 U (n=39) or 750 U (n=38) of BoNTA and were included in the full analysis set for efficacy analysis. Complete continence at day 30 was observed in 22 patients (56.4%) and 28 patients (73.7%) receiving 500 U or 750 U of BoNTA, respectively (p=0.056; one-sided χ(2) test to compare to α=0.025). The median delay in the reappearance of leakages was 168 d. Monotherapy of BoNTA significantly improved UI in patients with NDO. Although there was a trend towards a greater improvement with 750 U of BoNTA, no statistically significant differences in terms of clinical and urodynamic variables and QoL were found between the treatment groups. Tolerability was excellent and equivalent for both doses. CONCLUSIONS: Monotherapy of BoNTA at Dysport (Ipsen, Brisbane, CA, USA) doses of 500 U or 750 U seems to be effective and well tolerated in patients with NDO. |
| | |
Authors:
|
Philippe Grise; Alain Ruffion; Pierre Denys; Guy Egon; Emmanuel Chartier Kastler |
Related Documents
:
|
16032779 - Treatment of interstitial cystitis with cystistat: a hyaluronic acid product. 11257689 - Outcome of patients with prenatally detected duplex system ureterocele; natural history... 8401639 - Clinical experience with multiagent intravesical therapy in interstitial cystitis patie... 10452289 - Evaluation of kock urinary reservoir function in children and adolescents at 3-10 years... 17605019 - The urethral valve of guérin and lacuna magna: clinical presentations and urodynamic f... 11886599 - The efficacy of chondroitin sulfate 0.2% in treating interstitial cystitis. 12381639 - Surgical closure of atrial septal defects in adults: effect of age at operation on outc... 22534359 - Evaluation of neurosensory alterations via clinical neurosensory tests following anteri... 11401139 - Quality of life in aortic valve replacement: pulmonary autografts versus mechanical pro... |
Publication Detail:
|
Type: Journal Article Date: 2010-07-03 |
Journal Detail:
|
Title: European urology Volume: 58 ISSN: 1873-7560 ISO Abbreviation: Eur. Urol. Publication Date: 2010 Nov |
Date Detail:
|
Created Date: 2011-03-18 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 7512719 Medline TA: Eur Urol Country: Switzerland |
Other Details:
|
Languages: eng Pagination: 759-66 Citation Subset: IM |
Copyright Information:
|
Copyright © 2010. Published by Elsevier B.V. |
Affiliation:
|
Department of Urology, Rouen University Hospital, Rouen Cedex, France. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Treatment of E. coli HB101 and the tetM gene by Fenton's reagent and ozone in cow manure.
Next Document: Validation of the 2009 TNM version in a large multi-institutional cohort of patients treated for ren...